

# SCIENCE

Published by the **American Association for the Advancement of Science (AAAS)**, *Science* serves its readers as a forum for the presentation and discussion of important issues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in *Science*—including editorials, news and comment, and book reviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affiliated.

The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.

## Membership/Circulation

**Director:** Michael Spinella  
**Deputy Director:** Marlene Zendell  
**Member Services:** Rebecca Dickerson, *Manager*; Mary Curry, *Supervisor*; Pat Butler, Helen Williams, Laurie Baker, *Representatives*  
**Marketing:** Dee Valencia, *Manager*; Jane Pennington, *Europe Manager*; Hilary Baar, *Associate*; Angela Mumeka, *Coordinator*  
**Research:** Renuka Chander, *Manager*  
**Business and Finance:** Jacquelyn Roberts, *Manager*; Robert Smariga, *Assistant Manager*  
**Administrative Assistant:** Nina Araujo de Kobes  
**Science Member Services**  
Marion, Ohio: 800-347-6969;  
Washington, DC: 202-326-6417  
**Other AAAS Programs:** 202-326-6400

## Advertising and Finance

**Associate Publisher:** Beth Rosner  
**Advertising Sales Manager:** Susan A. Meredith  
**Recruitment Advertising Manager:** Janis Crowley  
**Business Manager:** Deborah Rivera-Wienhold  
**Finance:** Randy Yi, *Senior Analyst*; Shawn Williams, *Analyst*  
**Marketing:** John Meyers, *Manager*; Allison Pritchard, *Associate*  
**Traffic Manager:** Tina Turano  
**Recruitment:** Terri Seiter, *Assistant Manager*; Pamela Sams, *Production Associate*; Debbie Cummings, Celeste Miller, Rachael Wilson, *Sales*; Charlotte Longhurst, *European Sales*  
**Reprints Manager:** Corrine Harris  
**Permissions Manager:** Lincoln Richman  
**Exhibits Coordinator:** Arlene Ennis  
**Sales Associate:** Carol Maddox

## PRODUCT ADVERTISING SALES: East Coast/E.

**Canada:** Richard Teeling, 201-904-9774, FAX 201-904-9701 • **Midwest/Southeast:** Elizabeth Mosko, 312-665-1150, FAX 312-665-2129 • **West Coast/W. Canada:** Neil Boylan, 415-673-9265, FAX 415-673-9267 • **UK, Scandinavia, France, Italy, Belgium, Netherlands:** Andrew Davies, (44) 1-457-838-519, FAX (44) 1-457-838-898 • **Germany/Switzerland/Austria:** Tracey Peers, (44) 1-270-760-108, FAX (44) 1-270-759-597 • **Japan:** Mashy Yoshikawa, (3) 3235-5961, FAX (3) 3235-5852

## RECRUITMENT ADVERTISING SALES: US:

202-326-6555, FAX 202-682-0816 • **Europe:** Gordon Clark, (44) 1-81539-5211, FAX (44) 1223-302068 • **Australia/New Zealand:** Keith Sandell, (61) 02-922-2977, FAX (61) 02-922-1100

Send materials to *Science* Advertising, 1333 H Street, NW, Washington, DC 20005.

**Information for Contributors** appears on pages 112–114 of the 6 January 1995 issue. Editorial correspondence, including requests for permission to reprint and reprint orders, should be sent to 1333 H Street, NW, Washington, DC 20005.

**Internet addresses:** science\_editors@aaas.org (for general editorial queries); science\_letters@aaas.org (for letters to the editor); science\_reviews@aaas.org (for returning manuscript reviews); membership@aaas.org (for member services); science\_classifieds@aaas.org (for submitting classified advertisements)

# LETTERS

## NIH Review of Gene Therapy Protocols

Eliot Marshall's informative News & Comment article about the National Institutes of Health's (NIH's) efforts to review its activities in the area of gene therapy (17 Mar., p. 1588) merits some minor clarification.

First, the review activities were designed to involve more than one external committee. The panel described in the article, chaired by Inder Verma, is charged with evaluating the process by which human gene therapy protocols are approved by the NIH Recombinant DNA Advisory Committee (RAC). A second group, now being formed, will have a much broader mandate to examine research activities, especially those funded by NIH, in the gene therapy arena.

Second, I am not, as stated in the article, the first NIH director to defer a decision about a human gene therapy protocol after it was approved by a majority of RAC members. For example, in 1988 the RAC approved the first gene-marking protocol, submitted by Stephen A. Rosenberg, R. Michael Blaese, and W. French Anderson, by a vote of 16 to 5. James Wyngaarden requested that the proposal be reconsidered by the Human Gene Therapy Subcommittee after provision of additional data.

Third, important information is missing in the discussion of the protocols proposed by David Curiel and by Jeffrey Schlom. At the time Schlom proposed to conduct a "cancer vaccine" trial involving the use of a vaccinia vector encoding carcinoembryonic antigen, vaccines were defined in the *NIH Guidelines for Research Involving Recombinant DNA Molecules* in a manner that did not mandate review of such a protocol by the RAC. Subsequent to that time and before the submission of the Curiel protocol, the RAC deliberately changed the definition of vaccines so as to require review of the so-called "cancer vaccine" protocols. The fact that the Schlom protocol was not reviewed and the Curiel protocol was reviewed has nothing to do with the merits of either, but simply reflects a policy change made by the RAC.

**Harold Varmus**

*Director,  
National Institutes of Health,  
Bethesda, MD 20892, USA*

## Alzheimer Tangles and Abnormal Phosphorylation

The excellent and thought-provoking article "Protein studies try to puzzle out Alzheimer's tangles" by Wade Roush (Research News, 10 Feb., p. 793) describes recent experiments by John Trojanowski, Virginia Lee, and their colleagues at the University of Pennsylvania and by Gerald Fasman at Brandeis University. The research focuses on the events leading to the hyperphosphorylation of the microtubule-binding protein tau and the subsequent accumulation of this abnormal form of tau in the characteristic Alzheimer tangles. It is stated in the article that "Researchers turned first to kinases, enzymes that add phosphate groups to proteins. But no one could definitively catch a particularly active kinase in the act." I believe we did just that.

In 1991, H. M. Roder and I reported (1) that we had discovered a protein kinase that could convert tau in vitro into the hyperphosphorylated form found in Alzheimer tangles. This kinase, which we called PK40<sup>erk2</sup> because it is a member of the ERK family, was strongly inhibited in vitro by adenosine triphosphate (ATP) uncomplexed with Mg<sup>2+</sup> in the millimolar range. We proposed that the expected decrease of ATP concentrations in the brains of patients with Alzheimer's disease might upregulate the kinase, leading to hyperphosphorylated tau and therefore tangles. We have recently demonstrated (2) the hyperphosphorylation of tau (and of neurofilament proteins) in vivo, that is, in differentiated PC12 cells that were depleted in ATP by uncoupling oxidative phosphorylation or by inhibiting ATP synthesis. At the same time, and unexpectedly, protein phosphatase PP1 was found to be upregulated by an unknown mechanism, producing dephosphorylation of tau in one specific site, while the upregulated kinase hyperphosphorylated tau at some other site or sites. One supposes that the ability of tau to interact appropriately with microtubules depends on a precise distribution of phosphorylated and dephosphorylated sites.

The mechanisms are probably more complicated than those set out in the article. Active protein phosphatases might be one factor, but upregulated protein kinases are another. We need to look for explanations that would include both Trojanowski and Lee's and also Fasman's observations, as

well as ours. I do not know how rapidly ATP concentrations change after death, but it is clear that such changes are rapid and drastic after ischemia (3). I urge that rapid putative changes in ATP concentrations with their consequences be taken into account when postmortem observations are interpreted.

**Vernon M. Ingram**  
Department of Biology,  
Massachusetts Institute of Technology,  
Cambridge, MA 02139-4307, USA

#### References

1. H. M. Roder and V. M. Ingram, *J. Neurosci.* **11**, 3325 (1991); H. M. Roder, P. A. Eden, V. M. Ingram, *Biochem. Biophys. Res. Commun.* **183**, 639 (1993); H. M. Roder, R. P. Fracasso, F. J. Hoffman, *Research Advances in Alzheimer's Disease and Related Disorders*, K. Iqbal et al., Eds. (Wiley, New York, 1995).
2. M. L. Bush, J. S. Miyashiro, V. M. Ingram, *Proc. Natl. Acad. Sci. U.S.A.* **92**, 1861 (1995).
3. M. Szatkowski and D. Attwell, *Trends Neurosci.* **17**, 359 (1994).

#### Multidisciplinary Activities at the National Science Foundation

In Jeffrey Mervis's article (News & Comment, 3 Feb., p. 615) about the creation of the new Office of Multidisciplinary Activ-

ities (OMA) within the National Science Foundation's (NSF's) Directorate for Mathematical and Physical Sciences (MPS), Frank Shu, president of the American Astronomical Society, is quoted as saying that OMA was created without input from the community. Nothing could be further from the truth. The MPS Advisory Committee has believed for some time that an office like the OMA was needed to both engender and address growing research and educational activities involving other research and development agencies and the private sector, as well as to coordinate MPS activities within the NSF. While many were responsible for NSF multidisciplinary activities, the Advisory Committee saw the need to have an office that was specifically *accountable* for these important activities.

Following on these beliefs, the Advisory Committee worked with the MPS directorate's senior staff, as well as with many members of the community, to help draft the OMA. We sought broad input on the need for OMA and got strong, broad support for it. [We should also note that the Grant Opportunities program (GOALI) was approved before the existence of the OMA and is based on a rather successful model within the Division of Mathematical Sciences.]

Those with disciplinary-oriented inter-

ests are understandably concerned about the loss of resources to those who are interested in working with others in different disciplines. In our judgment, however, the creation of the new OMA represents a bold move on the part of the NSF—done in concert with the scientific community—to respond to the changing reality of today's research enterprise.

**Peter Eisenberger**  
Co-Chair, Mathematical and Physical  
Sciences Advisory Committee, and  
Director, Princeton Materials Institute,  
Princeton University,  
Princeton, NJ 08540, USA  
**Richard H. Herman**  
Co-Chair, Mathematical and Physical  
Sciences Advisory Committee, and  
Dean, Computer, Mathematical,  
and Physical Sciences,  
University of Maryland,  
College Park, MD 20742-3281, USA

#### Three-Dimensional Molecular Graphics

It is understandable that the protein crystallographers interviewed by Stephen S. Hall (Special News Report, 3 Feb., p. 620)



These new solid phase  
combs have done wonders  
for my sequencing.

Why would you  
need any combs?